CD86 and neoplasm: Accordingly, significant activation (MHCII+, CD86+) of DCs (CD45+CD11c+) in dLNs and expansion of CD8+ T cells (CD45+CD3+CD8+) in dLNs, spleen, and tumors were achieved when poly(I:C) and tumor cell lysates were incorporated in the HGs administered s.c. to the tissue i.l. to the tumor [171].